RRC ID 62953
著者 Liu W, Takahashi Y, Morishita M, Nishikawa M, Takakura Y.
タイトル Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response.
ジャーナル Nanomedicine (Lond)
Abstract Aim: Tumor-derived small extracellular vesicles (TEVs) are considered for use in inducing tumor antigen-specific immune responses as they contain tumor antigens. The delivery of tumor antigens to the antigen presentation cells (especially dendritic cells [DCs]), and the activation of DCs are the main challenges of TEV therapy. Materials & methods: TEVs were modified with CD40 ligand (CD40L), which can target CD40 expressed on the surface of DCs and can activate them via CD40L-CD40 interactions. Results: It was found that CD40L-TEVs were efficiently taken up by DCs and also activated them. Moreover, tumor antigens were efficiently presented to the T cells by DCs treated with CD40L-TEVs. Conclusion: This study proved that CD40L-modification of TEVs will be helpful for further development of TEV-based tumor vaccination.
巻・号 15(17)
ページ 1641-1652
公開日 2020-7-1
DOI 10.2217/nnm-2020-0071
PMID 32664826
MeSH CD40 Ligand* Dendritic Cells Extracellular Vesicles* Humans Immunity Neoplasms* / therapy
IF 4.3
リソース情報
ヒト・動物細胞 B16/BL6(RCB2638)